PreveCeutical Medical Inc (PRVCF)

[NetworkNewsWire]

PRVCF Details Research and Option Agreement with UniQuest Pty Limited

Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced and detailed its entry into a research and option agreement with the University of Queensland (“UQ”) and UniQuest Pty Limited, UQ’s main commercialization company. Per the terms of the agreement, the parties intend to conduct a research program aimed at expanding the use of their disulfide linker technology and developing non-addictive analgesics for the treatment of pain. The research program has a targeted start date of March 1, 2018, and is expected to be led by UQ researcher and PreveCeutical Chief Research Officer Dr. Harendra Parekh. PreveCeutical will own all intellectual property developed under the program and will be granted an option to negotiate an exclusive worldwide license to UniQuest’s background IP.

To view the full press release, visit http://nnw.fm/lH9Lz

About PreveCeutical Medical Inc.

PreveCeutical Medical Inc. is a health sciences company that develops innovative preventive therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose to brain delivery of medical compounds including cannabinoids; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9 is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. For more information, visit the company’s website at www.PreveCeutical.com